Gonzalo Recondo Julien Mazieres, Satoshi Yoda, many others 🌏 🙏 This Nature Cancer review picks up from where we left off with the ALK review authored w/ Gʀᴇɢᴏʀʏ Rɪᴇʟʏ in 2017 Cancer Discovery aacrjournals.org/cancerdiscover… @ALKLungCancer ALK+ International #LCSM MGH Thoracic Oncology Mass General Cancer Center [3/3]

How do you address resistance to first-line ROS1 TKI therapy in ROS1 fusion-positive lung cancers? Tune in as JessicaJLinMD from MGH Thoracic Oncology discusses the framework for considering later-line strategies at #TTLC23 IASLC #LCSM The ROS1ders, Inc. ROS1DERS UK Charity Mass General Cancer Center

And now for another installment of Meet the Grads! 🩺🎓 Name: Alissa Cooper, MD (and Dana-Farber/Mass General Brigham Chief Fellow!) Hometown: Winchester, MA Subspecialty: Thoracic Oncology MGH Thoracic Oncology Mass General Cancer Center Faculty position: Thoracic Oncologist Memorial Sloan Kettering Cancer Center

Our #Boston ALCSI team had a busy weekend raising #lungcancerawareness at the Mission Hill Farmer’s Market, Whittier Street Health Center Health Fair, and the Metropolitan Baptist Community Day. We had a great time getting to know our community and discussing #earlydetection of #lungcancer!!

Today in Nature - lung cancer targeted therapies can induce APOBEC3A, which drives evolution of acquired drug resistance. Terrific team effort led by Hata and Lawrence groups in collaboration with Zosia Piotrowska Lecia Sequist, MD, MPH JessicaJLinMD Justin Gainor nature.com/articles/s4158…

Congratulations to Dr. Jaime L. Schneider, M.D., Ph.D. on being invited as a Forbeck Foundation scholar to speak about systemic metabolism and #Cancer! Her #research focuses are identifying metabolic liabilities in #oncogene-driven lung cancers in hopes of developing new therapeutic strategies!

Excited to share the first presentation of the preliminary activity and safety results on NVL-655, new ALK TKI. Brief recap here. Efficacy in heavily pretreated ALK+ NSCLC. Thanks to AACR #Targets23 for the opportunity to present, to collaborators, patients ALK Positive #LCSM

Nice clearance of ALK mutations and CNS activity, and favorable safety profile! Hopeful news for patients. Alexander Drilon MD Benjamin Besse Sai-Hong Ignatius Ou Melissa L. Johnson Julien Mazieres Enriqueta Felip Yasir Yousif Elamin Shirish Gadgeel D. Ross Camidge Viola Zhu ALK+ International

Great day in Boston as a keynote speaker at the DF/HCC Lung Program Annual Symposium. Thank you for the invitation to be part of it. Enjoyed all the great science and discussion. #SCLC #LCSM Dana-Farber MGH Thoracic Oncology Lecia Sequist, MD, MPH, FASCO @cbmeador Justin Gainor Taofeek K Owonikoko OserLab

Drs. Lecia Sequist, MD, MPH, FASCO of Mass General Cancer Center and MGH Thoracic Oncology and @Colazagasti of @sylvestercancer discuss the I-ELCAP study results and their significance for lung cancer screening, as well as how we can do better. bit.ly/47cGXsM

🚨The future of #ThoracicOncology is in great hands! My co-chair colleague Dr Christian Rolfo, myself, great faculty mentors, & #IASLC staff are honored to kick off the: “2024 global IASLC #Academy.” Welcome to an outstanding group of #EarlyCareer #Physicians & #Researchers.

Dr. Lecia Sequist, MD, MPH, FASCO with a brilliant #ASCO24 discussion of LAURA and #EGFR NSCLC. Do we apply this paradigm now to subtypes with CNS active agents that have long term safety data like #ALK and #RET? I think so!

MGH Thoracic crew listening to not one but TWO plenary sessions by outstanding Mass General Cancer Center physicians—Dr. Joseph Greer/Dr. Jennifer Temel and Lecia Sequist, MD, MPH. 🙌🎉 So grateful to be training with this group! MGH Thoracic Oncology

Congratulations to Jaime L. Schneider, M.D., Ph.D. on receiving the “40 Under 40 in Cancer” award ASCO. This achievement recognizes Dr. Schneider’s contributions to the field of cancer as one of the nation’s most promising young oncology professionals impacting lives of many affected by #cancer.

Congratulations to @cbmeador for receiving the ASCO Conquer #Cancer Career Development Award for #research work studying liquid biopsies in #SCLC!

Dr. JessicaJLinMD from MGH Thoracic Oncology will discuss advances in targeting #ALK in advanced NSCLC at #DCLung24. Learn about the new wave of drugs! Join us Saturday, October 19th in downtown Washington, DC for this IASLC endorsed, one-day #CME meeting! medstarhealth.org/dclung24

Dr. Zosia Piotrowska from MGH Thoracic Oncology will discuss #EGFR in NSCLC and overcoming resistance at #DCLung24. This is a talk you do not want to miss! Join us Saturday, October 19th in downtown Washington, DC for this IASLC endorsed, one-day #CME meeting! medstarhealth.org/dclung24

Dr. I.DagogoJackMD brings us up to speed on systemic strategies for #mesothelioma at #DCLung24. With competing immunotherapy approaches, which is best Join us Saturday, October 19th in downtown Washington, DC for this IASLC endorsed, one-day #CME meeting! medstarhealth.org/dclung24

Despite progress, advanced ALK+ lung cancer almost always recurs. By deeply exploring the biology of cancer cells that resist treatment, the new PoweRD 2 Cure ALK+ Lung Cancer TeamLab aims to bend the survival curve for patients - JessicaJLinMD #RadicalCollaboration

Our latest edition of CancerScope: First Person Profile highlights #PalliativeCare pioneer Dr. Jennifer Temel, whose work has transformed the patient experience and improved health care delivery and outcomes. acsjournals.onlinelibrary.wiley.com/doi/epdf/10.10… Mass General Cancer Center MGH Thoracic Oncology OncoAlert